Wolin Jonathan S. 4

Accession 0001193125-26-018042

CIK 0001585608other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 4:30 PM ET

Size

7.9 KB

Accession

0001193125-26-018042

AI-generated summary of this filing

Updated Jan 21, 2026

Jaguar Health (JAGX) Jonathan Wolin, GC, Receives Equity Award

What Happened

Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer & General Counsel of Jaguar Health (JAGX), received equity awards on December 11, 2025: 11,740 restricted stock units (RSUs) and 11,740 option-related derivative awards. Both awards were granted at $0.00 (i.e., no cash payment by the recipient). Total award units granted = 23,480.

Key Details

Transaction date: December 11, 2025; Filing date (Form 4): January 21, 2026 (filed late relative to the typical 2-business-day rule).
Award types: 11,740 RSUs (contingent right to one share each) and 11,740 option-style derivative grants.
Vesting: RSUs vest on December 11, 2026 (per grant notice). Options vest ratably monthly over 12 months from the grant date, subject to continued employment.
Consideration: $0.00 reported for each grant (standard for compensatory awards).
Reverse split note: A 25-for-1 reverse stock split effected March 24, 2025 is noted by the issuer; share counts are presented with that split in mind.
Shares owned after transaction: Not specified in the provided filing excerpt.
Timeliness: The Form 4 was filed ~6 weeks after the grant date, which is later than the usual 2-business-day filing window and may reduce timely transparency.

Context

These are compensatory grants from the company’s 2014 Stock Incentive Plan approved by the board; RSUs are contingent rights to future shares and will not convert into actual shares until vesting. Options vest over time rather than immediately and do not indicate an immediate sale or cashless exercise.
Awards of this type are routine for executive compensation and should be viewed as part of pay structure rather than a market-timing signal.

Form 4

Period: 2025-12-11

See Remarks

Transactions

Award
Common Stock
[F1][F2][F3][F4]
2025-12-11+11,740→ 11,938 total
Award
Stock Option (right to buy)
[F1][F2][F5]
2025-12-11+11,740→ 11,740 total
Exercise: $1.44Exp: 2035-12-11→ Common Stock (11,740 underlying)

Footnotes (5)

[F1]Granted pursuant to the issuer's 2014 Stock Incentive Plan.
[F2]The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
[F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
[F4]On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
[F5]The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Signature

/s/ Jonathan S. Wolin|2026-01-21

1 file

Jaguar Health, Inc.

CIK 0001585608

Entity typeother